MNKD was $10/share when the FDA denied approval. Since then we have learned that the float will be increased by 2 fold and the market, both type-I and type-II, for Afrezza has not changed. Therefore, the new Pre-FDA approval price per share is $5. The warrants will not ALL be exercized this year and MNKD needs cash to build another production plant (the frozen Afrezza in storage is short-term). No one on the site has addressed this issue. In addition, no one one this site has addressed how much of the profits a partner will demand? The partner has the upper hand because MNKD needs their sales channel! Please, only those of you with the ability to provide an answer to these issue need respond. I am sick and tired of the clown parade posting their diatribe!
Hey Mitchb7518......thanks for the heads up! You appear well informed, as it looks like you have certainly done your homework! For certain...you have given me strong reasons to sell all my MNKD holdings and to move on. Now will you please move on as well...#$%$ hed!
Simple math does not work with biotechs, much more is involved with sp, ie, DNDN over $40, VVUS over $30, and many more.Emotion and momentum play a great part in run up sp.
Sentiment: Strong Buy
The 2nd CRL was issued for Afrezza as a T2 treatment only. The current clinical trials include Afrezza for both T1 and T2 = the market has expanded dramatically.
Pre-approval pps will be far above $5.
Partners are in line and MNKD will dictate the #s not the partners---but I believe a buy-out will occur.
MNKD can not and will not go it alone. Al's history is tech development and sale---this will not change.
Look for a buy-out prior to approval---DD of the clinical data will be the key.
with all due respect I think you mean the prior CRL was for T1 diabetes. Approximatly about 10% of all diabetics. The recent studies include T2 diabetics which drastically increase the market for Afrezza.In both cases it use as a prandial insulin only.
And aside from what others have already mentioned, the most important fact is that institutions and hedge funds are lined up on the side of MNKD this time around and want to see the share price explode. The hype will be greater than ever come August for the biotech stock of the decade.
The diabetes treatment market has also gone up quite a bit. But past fundamentals, market cap, etc. won't matter this time. The stock market and the big players who run it operate on hype, and you will bear witness to this here in MNKD in the coming months.
expanded label, and the market has changed/increased, and is projected to continue to so for the foreseeable future. Type II especially. I would like some answers on the role of a partner as well though.